Beta Bionics Inc. Common Stock (BBNX)
Stock · NASDAQ · Health Care
$16.35as of 10/16/2026
Price chart
Active signals
BBNX Signal Track Record
How signals performed across all stocks →What BBNX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 7 | -4.8% | 29% | September 3, 2026 |
| Bollinger Band Breakout | 5 | +0.9% | 60% | September 16, 2026 |
| Bollinger Band Breakdown | 5 | +2.2% | 60% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -1.5% | 33% | September 10, 2026 |
| Any 20-session window (baseline) | +0.9% | 50% |
Computed by MarketWall from daily closing prices since November 13, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 420
- Website
- www.betabionics.com
Fundamentals
- 1-day range
- $16.32$17.53
- Market cap
- $634.80M
- P/E (trailing)
- —
- P/E (forward)
- -7.57
- EPS (trailing)
- $-1.65
- Dividend yield
- —
- Beta
- 0.78
- Avg. volume
- 1.28M
How Beta Bionics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Beta Bionics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BBNXBeta Bionics Inc. Common Stock$16.35▼ 5.55%Market cap $634.80MP/E —$8.8$32.71
- BWAYBrainsWay Ltd. American Depositary Shares$11.44▼ 3.21%Market cap $626.52MP/E 53.55$2,391$5,123
- ANGOAngioDynamics Inc. Common Stock$11.24▼ 2.94%Market cap $624.53MP/E —$9.39$16.29
- TCMDTactile Systems Technology Inc. Common Stock$22.52▼ 3.31%Market cap $650.97MP/E 21.02$14.43$37.77
- MDXGMiMedx Group Inc Common Stock$4.43▼ 5.34%Market cap $609.28MP/E 109.34$3.03$7.97
- KIDSOrthoPediatrics Corp. Common Stock$21.95▼ 2.75%Market cap $549.03MP/E —$14.42$26.74
- DCTHDelcath Systems Inc. Common Stock$14.08▼ 4.93%Market cap $534.05MP/E 962.21$8.12$17.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BBNX Beta Bionics Inc. Common Stock | $634.80M | — | $16.35 | ▼ 5.55% | $8.8$32.71 |
| BWAY BrainsWay Ltd. American Depositary Shares | $626.52M | 53.55 | $11.44 | ▼ 3.21% | $2,391$5,123 |
| ANGO AngioDynamics Inc. Common Stock | $624.53M | — | $11.24 | ▼ 2.94% | $9.39$16.29 |
| TCMD Tactile Systems Technology Inc. Common Stock | $650.97M | 21.02 | $22.52 | ▼ 3.31% | $14.43$37.77 |
| MDXG MiMedx Group Inc Common Stock | $609.28M | 109.34 | $4.43 | ▼ 5.34% | $3.03$7.97 |
| KIDS OrthoPediatrics Corp. Common Stock | $549.03M | — | $21.95 | ▼ 2.75% | $14.42$26.74 |
| DCTH Delcath Systems Inc. Common Stock | $534.05M | 962.21 | $14.08 | ▼ 4.93% | $8.12$17.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target ChangesYahoo · 10/9/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Beta Bionics Stock Down Despite iLet-Eversense 365 Integration DealYahoo · 9/29/2026
- Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026Yahoo · 9/29/2026
- Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28Benzinga · 9/24/2026
- Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28Benzinga · 9/23/2026
- Sector Update: Healthcare Stocks Rise Late AfternoonYahoo · 9/22/2026
- Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365Yahoo · 9/22/2026
- Senseonics Partners With Beta Bionics To Integrate Its Eversense 365 CGM With Beta Bionics’ iLet Bionic Pancreas Automated Insulin Delivery Systembenzinga · 9/14/2026
Insider Activity
Insider Actions →- Mark Hopman · October 1, 2026 · Sale370 @ $18.96
- Christy Jones · September 22, 2026 · Sale6.4K @ $23
- Mike Mensinger · September 16, 2026 · Sale2.6K @ $22
- Mark Hopman · September 16, 2026 · Sale30.8K @ $20.13
- Mark Hopman · September 14, 2026 · Sale775 @ $15.52
- Mark Hopman · September 9, 2026 · Sale36.9K @ $18.46
- Mark Hopman · September 9, 2026 · Sale36.0K @ $18.46
- Sean Saint · September 3, 2026 · Sale5.6K @ $20.08
- Steven Jon Russell · September 2, 2026 · Sale4.2K @ $19.11
- Sean Saint · September 2, 2026 · Sale16.9K @ $19.11
- Stephen Feider · September 2, 2026 · Sale6.7K @ $19.11
- Mike Mensinger · September 2, 2026 · Sale4.4K @ $19.11
- Mark Hopman · September 2, 2026 · Sale5.3K @ $19.11
- Stephen Feider · June 29, 2026 · Option Exercise4.9K @ $5.1
- Stephen Feider · June 29, 2026 · Sale4.9K @ $17.03
Institutional Ownership
March 31, 2026
- Total shares held
- 48.55M
- Total value held
- $486.76M
- Institutional holders
- 127
- Unknown5.95M
- Unknown4.35M
- Unknown4.23M
- Unknown3.71M
- Unknown3.61M
- Unknown3.04M
- Unknown2.53M
- Unknown2.21M
- Unknown2.00M
- Unknown1.73M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage
Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage. Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.